Particle.news
Download on the App Store
3 ARTICLES
·
2w ago

Regeneron, Tessera Strike $150 Million Gene-Editing Pact for Alpha‑1 Antitrypsin Deficiency

The one-time in vivo candidate TSRA-196 targets correction of SERPINA1 mutations, with Tessera planning an FDA filing by year-end.

Regeneron and Tessera have partnered to develop and commercialise TSRA-196, an in vivo gene therapy that could potentially cure AATD. Image credit: Corona Borealis Studio via Shutterstock.com.
Image

Overview

  • Regeneron will pay $150 million upfront in cash and equity, with Tessera eligible for up to $125 million in additional development milestones.
  • The partners will split development costs and any future profits 50:50, while Regeneron secures half of global rights to TSRA-196.
  • Tessera will conduct the initial first-in-human study following IND/CTA clearance, and Regeneron will assume later global development and commercialization if early results support progression.
  • Preclinical studies reported durable SERPINA1 editing after a single dose in mice and non-human primates using Tessera’s in vivo Gene Writing platform.
  • If proven safe and effective, TSRA-196 could become the first disease-modifying treatment for AATD, a rare condition with limited non-curative therapies and competing RNA and gene-editing programs.